期刊文献+

甲磺酸沙芬酰胺新合成工艺

New synthetic process of safinamide mesilate
原文传递
导出
摘要 报道了一种合成抗帕金森药甲磺酸沙芬酰胺的新工艺。它是以对羟基苯甲醛和间氟氯苯为起始物料,经醚化、还原、卤代、缩合和成盐制得甲磺酸沙芬酰胺,总收率为58.2%,纯度达99.5%。该新工艺操作简便,产品纯度高,适合工业化生产。 A new synthetic process of safinamide mesilate,an anti-parkinson drug was reported.Using 3-fluorobenzyl chloride and p-hydroxybenzaldehyde as the starting material,safinamide mesylate was synthesized through five steps,including etherification,reduction,halogenation,substitution and salification with a total yield of 58.2%and a purity of 99.5%.This process has some advantages such as convenient operations,high purity and suitable for industrial production.
作者 王进家 刘飞 章泽洲 柴雨柱 徐丹 朱春霞 WANG Jin-jia;LIU Fei;ZHANG Ze-zhou;CHAI Yu-zhu;XU Dan;ZHU Chun-xia(Nanjing Chia Tai-Tianqing Pharmaceutical Co.,Ltd.,Nanjing 210046,China)
出处 《精细与专用化学品》 CAS 2021年第7期43-45,共3页 Fine and Specialty Chemicals
关键词 甲磺酸沙芬酰胺 抗帕金森药物 合成 safinamide mesilate anti-parkinson drug synthesis
  • 相关文献

参考文献4

二级参考文献80

  • 1桑艳双,魏敏吉.辅酶Q_(10)的生化作用机理和药物临床应用进展[J].中国医药导刊,2005,7(5):371-373. 被引量:21
  • 2张成根,李文佐,黄明宝.溶液中甲醇和二氯亚砜的化学反应[J].物理化学学报,2007,23(3):399-403. 被引量:7
  • 3杨宝峰.药理学[M].北京:人民卫生出版社,2006:247-248.
  • 4Braak H,Del Tredici K,Rub U,et al.Staging of brain pathology related to sporadic Parkinson's disease[J].Neurobiol,2003,24 (2):197-211.
  • 5Beyer K,Ariza A.Protein aggregation mechanisms in synucleinopathies:commonalities and differences[J].J Neuropathol Exp Neurol,2007,66(11):965-974.
  • 6Blindauer K.Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson's disease patients with motor fluctuations[J].Neurology,2003,60(1):81-82.
  • 7Tatton W,Chalmers-Redman R,Tatton N.Neuroprotection by deprenyl and other propargylamines:giyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B[J].J Neural Transm,2003,110(8):509-515.
  • 8Parkinson Study Group.A controlled trial of rasagiline in early Parkinson's disease:the TEMPO Study[J].Arch Neurol,2002,59(12):1937-1943.
  • 9Rascol O,Brooks DJ,Melamed E,et al.Rasagiline as an adjunt to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO,Lasting effect in Adjunct therapy with Rasagiline Given Once daily,study):a randomized double-blind,parallel-group trial[J].Lancet,2005,365 (9643):947-954.
  • 10Olanow CW,Hauser RA,Jankovic J,et al.A randomized,double-blind,placebo-controlled,delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's Disease (The ADAGIO Study):rationale,design and baseline characteristics[J].Mov Disord,2008,23 (15):2194-2201.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部